286 related articles for article (PubMed ID: 26918448)
61. miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
Lindholm EM; Leivonen SK; Undlien E; Nebdal D; Git A; Caldas C; Børresen-Dale AL; Kleivi K
Microrna; 2019; 8(2):155-165. PubMed ID: 30520388
[TBL] [Abstract][Full Text] [Related]
62. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer.
Lu M; Wang T; He M; Cheng W; Yan T; Huang Z; Zhang L; Zhang H; Zhu W; Zhu Y; Liu P
Oncotarget; 2017 Apr; 8(14):23008-23019. PubMed ID: 28160563
[TBL] [Abstract][Full Text] [Related]
63. HER2 drives Mucin-like 1 to control proliferation in breast cancer cells.
Conley SJ; Bosco EE; Tice DA; Hollingsworth RE; Herbst R; Xiao Z
Oncogene; 2016 Aug; 35(32):4225-34. PubMed ID: 26725324
[TBL] [Abstract][Full Text] [Related]
64. Anesthetic propofol epigenetically regulates breast cancer trastuzumab resistance through IL-6/miR-149-5p axis.
Tian D; Tian M; Ma ZM; Zhang LL; Cui YF; Li JL
Sci Rep; 2020 Jun; 10(1):8858. PubMed ID: 32483313
[TBL] [Abstract][Full Text] [Related]
65. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.
Ferracin M; Bassi C; Pedriali M; Pagotto S; D'Abundo L; Zagatti B; Corrà F; Musa G; Callegari E; Lupini L; Volpato S; Querzoli P; Negrini M
Mol Cancer; 2013 Oct; 12(1):130. PubMed ID: 24165569
[TBL] [Abstract][Full Text] [Related]
66. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3.
Muhammad N; Bhattacharya S; Steele R; Ray RB
Oncotarget; 2016 Sep; 7(36):58595-58605. PubMed ID: 27517632
[TBL] [Abstract][Full Text] [Related]
67. MicroRNA signature for HER2-positive breast and gastric cancer.
Kang HS; Jang SG; Kwon SY; Park YS; Green JE; Kim HK; Ro J
Anticancer Res; 2014 Jul; 34(7):3807-10. PubMed ID: 24982406
[TBL] [Abstract][Full Text] [Related]
68. MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.
Ho JY; Hsu RJ; Liu JM; Chen SC; Liao GS; Gao HW; Yu CP
Oncotarget; 2017 Apr; 8(14):22443-22459. PubMed ID: 27705918
[TBL] [Abstract][Full Text] [Related]
69. FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.
Liu T; Zhang H; Sun L; Zhao D; Liu P; Yan M; Zaidi N; Izadmehr S; Gupta A; Abu-Amer W; Luo M; Yang J; Ou X; Wang Y; Bai X; Wang Y; New MI; Zaidi M; Yuen T; Liu C
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7683-7688. PubMed ID: 28674022
[TBL] [Abstract][Full Text] [Related]
70. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
[TBL] [Abstract][Full Text] [Related]
71. Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Hu Z; Fang H; Wang X; Chen D; Chen Z; Wang S
Oncol Rep; 2014 Jul; 32(1):205-12. PubMed ID: 24858400
[TBL] [Abstract][Full Text] [Related]
72. AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.
Zhang J; Yin YT; Wu CH; Qiu RL; Jiang WJ; Deng XG; Li ZX
Dis Markers; 2019; 2019():8186091. PubMed ID: 31827645
[TBL] [Abstract][Full Text] [Related]
73. HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.
Haghnavaz N; Asghari F; Elieh Ali Komi D; Shanehbandi D; Baradaran B; Kazemi T
Artif Cells Nanomed Biotechnol; 2018 May; 46(3):518-523. PubMed ID: 28509576
[TBL] [Abstract][Full Text] [Related]
74. Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.
Tang Y; Yang S; Wang M; Liu D; Liu Y; Zhang Y; Zhang Q
Int J Mol Med; 2019 Jun; 43(6):2352-2360. PubMed ID: 31017268
[TBL] [Abstract][Full Text] [Related]
75. SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane.
Li H; Zhang M; Wei Y; Haider F; Lin Y; Guan W; Liu Y; Zhang S; Yuan R; Yang X; Yang S; Wang H
J Exp Clin Cancer Res; 2020 May; 39(1):81. PubMed ID: 32381043
[TBL] [Abstract][Full Text] [Related]
76. A Designed Small Molecule Inhibitor of a Non-Coding RNA Sensitizes HER2 Negative Cancers to Herceptin.
Costales MG; Hoch DG; Abegg D; Childs-Disney JL; Velagapudi SP; Adibekian A; Disney MD
J Am Chem Soc; 2019 Feb; 141(7):2960-2974. PubMed ID: 30726072
[TBL] [Abstract][Full Text] [Related]
77. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.
Gorbatenko A; Søkilde R; Sorensen EE; Newie I; Persson H; Morancho B; Arribas J; Litman T; Rovira C; Pedersen SF
Sci Rep; 2019 Mar; 9(1):3352. PubMed ID: 30833639
[TBL] [Abstract][Full Text] [Related]
78. miR-433 inhibits breast cancer cell growth via the MAPK signaling pathway by targeting Rap1a.
Zhang T; Jiang K; Zhu X; Zhao G; Wu H; Deng G; Qiu C
Int J Biol Sci; 2018; 14(6):622-632. PubMed ID: 29904277
[TBL] [Abstract][Full Text] [Related]
79. Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.
Lv Y; Sui F; Ma J; Ren X; Yang Q; Zhang Y; Guan H; Shi B; Hou P; Ji M
Oncotarget; 2016 Sep; 7(36):57978-57990. PubMed ID: 27517321
[TBL] [Abstract][Full Text] [Related]
80. A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance.
Si W; Shen J; Du C; Chen D; Gu X; Li C; Yao M; Pan J; Cheng J; Jiang D; Xu L; Bao C; Fu P; Fan W
Cell Death Differ; 2018 Feb; 25(2):406-420. PubMed ID: 29125598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
